Wiesław Cubała
Professor and Head of the Department of Psychiatry, Medical University of Gdańsk
Data updated
Research Footprint
Wiesław Cubała appears in 6 tracked papers (2020–2026), most studied alongside Ketamine and 5-MeO-DMT, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Schizophrenia.
Most-cited paper: Antianhedonic Effect of Repeated Ketamine Infusions in Patients With Treatment Resistant Depression (35 citations).
Frequent co-authors: Tomáš Páleníček, Johannes Ramaekers and Bernhard Baune.
Background & Research
Wiesław Jerzy Cubała is a psychiatrist and academic clinician at the Medical University of Gdańsk in Poland, where he leads the Department of Psychiatry. His research focuses on mood disorders, anxiety disorders, and psychopharmacology, with a particular emphasis on ketamine/esketamine use in depression and bipolar depression. He has published multiple studies and reviews on ketamine’s efficacy, tolerability, and safety in real-world psychiatric care.
Key Impact
He is a leading Polish psychiatrist whose research has helped shape clinical and safety evidence for ketamine and esketamine in treatment-resistant depression and bipolar disorder.
Collaboration Network
6 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Wiesław Cubała is associated with.
Medical University of Gdansk
The Medical University of Gdańsk is Poland's leading academic medical institution, with its Department of Psychiatry running one of the country's most active research programs on ketamine and esketamine for treatment-resistant depression and bipolar disorder.
View stakeholder →GH Research
Public BiotechGH Research plc (NASDAQ: GHRS) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Dublin, Ireland, developing novel mebufotenin (5-MeO-DMT) therapeutics for treatment-resistant depression, bipolar II disorder, and postpartum depression. Its lead asset GH001 — an inhaled mebufotenin formulation — met the primary endpoint of its Phase 2b TRD trial in February 2025 with striking results: -15.5 point MADRS reduction vs placebo (p<0.0001) and 57.7% remission vs 0%. With a single-day dosing paradigm requiring no structured psychotherapy, GH001 is positioned as a differentiated asset; Phase 3 global initiation is planned for 2026 following FDA clinical hold lift. GH002 (IV mebufotenin) completed Phase 1 in healthy volunteers.
View stakeholder →